These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11879557)

  • 21. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
    Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology and clinical efficacy of bisphosphonates.
    Berenson JR; Lipton A
    Curr Opin Oncol; 1998 Nov; 10(6):566-71. PubMed ID: 9818237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.
    Fleisch H
    Horm Metab Res; 1997 Mar; 29(3):145-50. PubMed ID: 9137986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of bisphosphonates.
    Reszka AA; Rodan GA
    Curr Osteoporos Rep; 2003 Sep; 1(2):45-52. PubMed ID: 16036064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
    van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
    Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
    Drake MT; Cremers SC
    Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.
    Fleisch H
    Recent Results Cancer Res; 1989; 116():1-28. PubMed ID: 2669065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Frith JC; Luckman SP; Coxon FP; Benford HL; Mönkkönen J; Auriola S; Chilton KM; Russell RG
    Bone; 1999 May; 24(5 Suppl):73S-79S. PubMed ID: 10321934
    [No Abstract]   [Full Text] [Related]  

  • 34. New insights into the molecular mechanisms of action of bisphosphonates.
    Rogers MJ
    Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of bisphosphonates in arthroplasty].
    Brankamp J; Eberhardt C; Landgräber S; von Knoch M; Saxler G; Löer F; Kurth AA
    Z Orthop Ihre Grenzgeb; 2006; 144(2):187-91. PubMed ID: 16625449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
    Fleisch H
    Drugs; 1991 Dec; 42(6):919-44. PubMed ID: 1724640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of bisphosphonates].
    Nakatsuka K
    Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.